WO2021057987A1 - 检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途 - Google Patents

检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途 Download PDF

Info

Publication number
WO2021057987A1
WO2021057987A1 PCT/CN2020/118201 CN2020118201W WO2021057987A1 WO 2021057987 A1 WO2021057987 A1 WO 2021057987A1 CN 2020118201 W CN2020118201 W CN 2020118201W WO 2021057987 A1 WO2021057987 A1 WO 2021057987A1
Authority
WO
WIPO (PCT)
Prior art keywords
teratozoospermia
calprotectin
reagent
reagents
kit
Prior art date
Application number
PCT/CN2020/118201
Other languages
English (en)
French (fr)
Inventor
陆华
张琦
刘芊辰
廖睿
Original Assignee
成都中医药大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 成都中医药大学 filed Critical 成都中医药大学
Publication of WO2021057987A1 publication Critical patent/WO2021057987A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction

Definitions

  • the invention belongs to the field of disease screening kits.
  • Calprotectin was first isolated from neutrophils by Fagerhol in 1980 and named L1 protein. It was named after the discovery that its structure contains calcium and has antimicrobial properties. It has a history of 39 years as of today. In 1988, Wilkinson et al. named calgranulin based on this antigenic characteristic. Dorin and Freemont et al. further confirmed that these proteins have the structural characteristics of S-100 protein. Later, they named this protective calcium-binding protein with multiple functions. It is calprotectin.
  • Calprotectin is a heterodimeric complex composed of S100A8 and S100A9 in the S100 calcium binding protein family. It is a calcium-zinc binding protein derived from neutrophils and macrophages. It can be detected in serum, body fluids or feces. It has been identified as a marker of inflammatory bowel disease IBD. At present, elevated levels of calprotectin (S100A8/S100A9) can be detected in people with inflammation, tumor cells and cancer.
  • Fecal calprotectin (faecal calprotectin, FC) is the calprotectin in feces. Studies have shown that detecting the content of fecal calprotectin in feces can be used to diagnose ulcerative colitis and Crohn's disease.
  • the purpose of the present invention is to provide the use of a reagent for detecting the content of fecal calprotectin in preparing a teratozoospermia screening kit, and a new teratozoospermia screening kit.
  • the technical scheme of the present invention includes:
  • the reagents for detecting calprotectin in feces are: reagents for immunohistochemical detection methods, reagents for Western blot detection methods, reagents for colloidal gold methods, or reagents for ELISA detection methods.
  • the reagents also include protein purification reagents.
  • the kit detects that the content of calprotectin in the stool of a male subject is greater than that of a normal male, the male subject is at high risk of teratozoospermia.
  • a screening kit for teratozoospermia which includes a reagent for detecting calprotectin in feces.
  • the reagents for detecting calprotectin in feces are: reagents for immunohistochemical detection methods, reagents for Western blot detection methods, reagents for colloidal gold methods, or reagents for ELISA detection methods.
  • the male subject is at high risk of teratozoospermia.
  • the present invention detects the content of fecal calprotectin in different populations and finds that the content is significantly associated with teratozoospermia. With the help of this principle, a kit is developed, which can quickly and non-invasively screen teratozoospermia, and has a good application prospect.
  • Figure 1 Distribution interval statistics of fecal calprotectin content in patients with various teratozoospermia.
  • FC refers to fecal calprotectin.
  • Pre-coated plate Ninety-six-well plate coated with anti-human calprotectin rabbit IgG antibody on the inner wall and bottom of the well.
  • Chromogenic agent TMB substrate solution.
  • sample standard product
  • the standard curve can be prepared in advance with gradient dilution standards according to the aforementioned steps, and the sample concentration can be adjusted when the sample is formally tested, so that the concentration falls within the linear interval (the curve of concentration and OD value).
  • the screening kit of the present invention can also be prepared as follows:
  • Example 2 The relationship between teratozoospermia and the content of fecal calprotectin (FC)
  • the inventor performed a fecal calprotectin test on 49 teratozoospermia patients (normal sperm rate ⁇ 4%) in the outpatient clinic of the affiliated Hospital of Chengdu University of Traditional Chinese Medicine from 2019.06 to 2020.09 (using the calcium guard of Xiamen Weizheng Biotechnology Co., Ltd.) Protein detection kit (colloidal gold method)).
  • the detection method is as follows:
  • FC content ⁇ 15ug/g was considered positive (FC positive).
  • 49 male patients with teratozoospermia with an average age of 38.486 ⁇ 8.224 years, 6 cases with FC ⁇ 15ug/g, accounting for 12.24%; 43 cases with FC ⁇ 15ug/g, accounting for 93.47% (Table 1), ⁇ 60ug/g 11 cases, accounting for 22.448%, the highest value was 730ug/g, and the positive calcium guard value was 88.864 ⁇ 70.739ug/g (Table 2).
  • the increased FC value was mainly concentrated in the 60-240ug/g range (as shown in Figure 1), with a total of 30 cases, accounting for 61.224%.
  • FC ⁇ 15ug/g and FC ⁇ 15ug/g the mean FC of healthy men and teratozoospermia patients will be lowered because of the partial data of FC negative (FC ⁇ 15ug/g).
  • FC ⁇ 15ug/g the proportion of healthy men with FC ⁇ 15ug/g is significantly greater than that of teratozoospermia patients.
  • the average FC value of healthy men will be lower in the FC-negative part of the data, and the difference between healthy men and teratozoospermia patients will be greater. It can be seen that the FC values of healthy men and patients with teratozoospermia are very different from a global perspective.
  • the FC value can be used to distinguish healthy men from patients with teratozoospermia.
  • teratozoospermia is related to calprotectin in feces, and the kit of the present invention can quickly screen teratozoospermia by detecting calprotectin in stool samples.

Abstract

本发明提供了检测粪便中钙卫蛋白(粪钙卫蛋白)中含量的试剂在制备畸形精子症筛查试剂盒中的用途，属于疾病检测试剂盒领域。本发明通过对不同人群粪钙卫蛋白的含量的检测，发现该含量与畸形精子症关联显著，借助该原理开发出试剂盒，能够对畸形精子症进行快速、无创的筛查，应用前景良好。

Description

检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途 技术领域
本发明属于疾病筛查试剂盒领域。
背景技术
钙卫蛋白最早由Fagerhol于1980年从中性粒细胞分离，并命名为L1蛋白，后因发现其结构中含有钙并有抗微生物的特性而命名，截至今日已有39年历史。1988年Wilkinson等根据此种抗原特征又命名为钙粒蛋白，Dorin和Freemont等进一步证实这些蛋白质具有S-100蛋白质的结构特征，后来将此种具有保护性的多种功能的与钙结合蛋白质命名为钙卫蛋白。
钙卫蛋白是由S100钙结合蛋白家族中的S100A8和S100A9组成的异二聚体复合物，来源于中性细胞和巨噬细胞的钙－锌结合蛋白质，可在血清、体液或粪便中检测，己被确定为炎症性肠病IBD的标志物，目前可在炎症、肿瘤细胞和癌症人群中检测到钙卫蛋白(S100A8/S100A9)水平升高。
粪钙卫蛋白(faecal calprotectin，FC)即粪便中的钙卫蛋白，有研究表明，检测粪便中粪钙卫蛋白含量可用于诊断溃疡性结肠炎和克罗恩病。
但目前未见畸形精子症与钙卫蛋白的关系，更未见畸形精子症与粪便中钙卫蛋白(粪钙卫蛋白，faecal calprotectin，FC)的关系。
发明内容
本发明的目的在于提供检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途，以及一种新的畸形精子症筛查试剂盒。
本发明的技术方案包括：
检测粪便中的钙卫蛋白的试剂在制备畸形精子症筛查试剂盒中的用途。
如前述的用途，所述检测粪便中的钙卫蛋白的试剂为：免疫组化检测方法用试剂、Western Blot检测方法用试剂、胶体金方法用试剂或ELISA检测方法用试剂。
如前述的用途，所述试剂还包括蛋白纯化试剂。
如前述的用途，若所述试剂盒检测到男性被检者粪便中钙卫蛋白含量大于正常男性，则该男性被检者患畸形精子症风险高。
一种畸形精子症筛查试剂盒，所述试剂盒包括检测粪便中钙卫蛋白的试剂。
如前述的试剂盒，所述检测粪便中的钙卫蛋白的试剂为：免疫组化检测方法用试剂、Western Blot检测方法用试剂、胶体金方法用试剂或ELISA检测方法用试剂。
如前述的试剂盒，它还包括蛋白纯化试剂。
如前述的试剂盒，所述试剂盒检测到男性被检者粪便中钙卫蛋白含量大于正常男性，则该男性被检者患畸形精子症风险高。
本发明通过对不同人群粪钙卫蛋白的含量的检测，发现该含量与畸形精子症关联显著，借助该原理开发出试剂盒，能够对畸形精子症进行快速、无创的筛查，应用前景良好。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1：各类畸形精子症的患者中粪钙卫蛋白含量分布区间统计。
附图中，FC指粪钙卫蛋白。
具体实施方式
实施例1本发明筛查试剂盒(ELISA)
1.组成
(1)预包被板：孔内壁及底部包被了抗人钙卫蛋白兔IgG抗体的九十六孔板。
(2)酶标抗体：(30倍浓缩)HRP标记抗人钙卫蛋白兔IgG抗体。
(3)标准品：钙卫蛋白。
(4)缓冲液:含1％BSA、0.05％吐温20的PBS。
(5)显色剂:TMB底物液。
(6)终止液：1N硫酸。
2.样本制备
(1)使用样本采样专用粘附器采集标本，将大便排在展开的粘附器中央，注意大便不能沾到尿液、血液、厕水、厕纸等污染物；
(2)用取样棒插进粪便样本，然后将取样棒放回装有样本稀释液的粪便采样管内，旋紧、摇匀，以上动作重复3次；
(3)每次在同一粪便样本的多个不同部点进行取样，总取样量约50mg(近似火柴头大小)；
(4)旋紧取样管，摇匀待用；
(5)若腹泻患者，用一次性吸管吸取稀薄粪便，采集约100uL(3滴)至粪便采样管中，充分摇匀待用，尽快进行检测。
3.使用
(1)将样本(标准品)0.1mL加入预包被板孔内，37℃孵育30min，倒掉孔内液体，拍打3次，减少液体附着；
(2)加0.15mL缓冲液洗涤未结合到预包被板的蛋白，重复5次；
(3)加入酶标抗体0.1mL，37℃孵育30min，倒掉酶标抗体，加0.15mL缓冲液洗涤5次；
(4)加显色剂0.1mL，37℃孵育10min；
(5)加终止液0.05mL；
(6)结果判定：肉眼观察颜色深浅，颜色越深，阳性程度越强；或测OD值(450nm)。
可提前用梯度稀释标准品按前述步骤制备标准曲线，并在正式检测样本时调整样本浓度，使浓度落在线性区间(浓度与OD值的曲线)内。
本发明的筛查试剂盒还可以按如下方法制备得到：
将任意商用蛋白检测试剂盒中对应的蛋白标准品换成钙卫蛋白溶液，将抗体替换成抗钙卫蛋白抗体即可。
实施例2畸形精子症与粪钙卫蛋白(FC)的含量关系
发明人于2019.06-2020.09对成都中医药大学附属医院门诊就诊的49名畸形精子症患者(正常精子率＜4％)进行了粪钙卫蛋白检测(使用厦门为正生物科技股份有限公司的钙卫蛋白检测试剂盒(胶体金法))。
检测方法如下：
1.患者检测前准备
(1)第一次检测患者必须在服药、灌肠前采集检测样本；
(2)复查患者需在停药至少24小时后采样；
(3)采样前24小时饮食最好与平日饮食相似，避免暴饮暴食或服用过多辛辣刺激类食物，禁止饮酒；
(4)采样前一晚不可熬夜(保证睡眠时长≥6个小时)；
(5)月经经期时不宜进行采样；
(6)条件若允许尽量采集患者清晨第一次排便的粪便标本进行检测；
(7)不能按照采样要求进行采样的患者不宜进行检测。
2.样本采集与检测
(1)使用样本采样专用粘附器采集标本，将大便排在展开的粘附器中央，注意大便不能沾到尿液、血液、厕水、厕纸等污染物；
(2)用取样棒插进粪便样本，然后将取样棒放回装有样本稀释液的粪便采样管内，旋紧、摇匀，以上动作重复3次；
(3)每次在同一粪便样本的多个不同部点进行取样，总取样量约50mg(近似火柴头大小)；
(4)旋紧取样管，摇匀待用；
(5)若腹泻患者，用一次性吸管吸取稀薄粪便，采集约100uL(3滴)至粪便采样管中，充分摇匀待用，尽快进行检测；
(6)将配套的检测卡从铝箔袋中取出，做好标记并平放于水平工作台上；
(7)将采样管帽盖旋开，弃掉头两滴稀释样本，在检测卡加样孔中心缓慢、垂直的滴加100uL(3滴)无气泡稀释标本，将检测卡插入粪钙卫蛋白检测仪，并开始计时；
(8)在10-15min内进行结果判读，15min后检验结果无效。
结果显示：以FC含量≥15ug/g为阳性(FC阳性)。49例畸形精子症男性患者，平均年龄38.486±8.224岁，FC＜15ug/g者6例，占12.24％；FC≥15ug/g者43例，占93.47％(表1)，≥60ug/g者11例，占比22.448％，最高值达730ug/g，阳性者钙卫值88.864±70.739ug/g(表2)。其中升高的FC值主要集中在60-240ug/g区间(如图1)，共30例，占比61.224％。以32例健康男性(排除了畸形精子症的男性)对照，平均年龄35.355±8.122岁，FC＜15ug/g的有24个，占75％，FC≥15ug/g有8个，阳性者钙卫值(23.813±8.306)ug/g(表2)，两组FC阳性值差异具有统计学意义(P＜0.05)。
表1 男性畸形精子症FC阳性率(FC含量≥15ug/g)
Figure PCTCN2020118201-appb-000001
Figure PCTCN2020118201-appb-000002
表2 FC阳性的男性畸形精子症与健康男性比较
Figure PCTCN2020118201-appb-000003
从全局考虑(包括FC<15ug/g和FC≥15ug/g的情形)，健康男性和畸形精子症患者FC均值会均会因为FC阴性(FC<15ug/g)部分数据拉低。但健康男性的FC<15ug/g的比例明显大于畸形精子症患者，健康男性的FC均值会FC阴性部分数据拉得更低，健康男性和畸形精子症患者FC值的差异会更大。可见，健康男性和畸形精子症患者FC值从全局看，差异非常显著，可以通过FC值区分健康男性和畸形精子症患者。
本实施例表明，畸形精子症患者FC含量显著高于健康男性，FC含量高的男性患有畸形精子症的风险较高。
综上，畸形精子症与粪便中钙卫蛋白相关，本发明的试剂盒可通过对粪便样本中钙卫蛋白的检测，快速筛查畸形精子症。

Claims (10)

  1. 检测粪便中的钙卫蛋白的试剂在制备畸形精子症筛查试剂盒中的用途。
  2. 如权利要求1所述的用途，其特征在于，所述检测粪便中的钙卫蛋白的试剂为：免疫组化检测方法用试剂、Western Blot检测方法用试剂、胶体金方法用试剂或ELISA检测方法用试剂。
  3. 如权利要求1所述的用途，其特征在于：所述试剂还包括蛋白纯化试剂。
  4. 如权利要求1-3任一所述的用途，其特征在于，若所述试剂盒检测到男性被检者粪便中钙卫蛋白含量大于正常男性，则该男性被检者患畸形精子症风险高。
  5. 一种畸形精子症筛查试剂盒，其特征在于：所述试剂盒包括检测粪便中钙卫蛋白的试剂。
  6. 如权利要求5所述的试剂盒，其特征在于：所述检测粪便中的钙卫蛋白的试剂为：免疫组化检测方法用试剂。
  7. 如权利要求5所述的试剂盒，其特征在于：所述检测粪便中的钙卫蛋白的试剂为：胶体金方法用试剂。
  8. 如权利要求5所述的试剂盒，其特征在于：所述检测粪便中的钙卫蛋白的试剂为：ELISA检测方法用试剂。
  9. 如权利要求5所述的试剂盒，其特征在于：所述检测粪便中的钙卫蛋白的试剂为：Western Blot检测方法用试剂。
  10. 如权利要求5所述的试剂盒，其特征在于：所述试剂还包括蛋白纯化试剂。
PCT/CN2020/118201 2019-09-27 2020-09-27 检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途 WO2021057987A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910932036.6 2019-09-27
CN201910932036 2019-09-27

Publications (1)

Publication Number Publication Date
WO2021057987A1 true WO2021057987A1 (zh) 2021-04-01

Family

ID=75119796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/118201 WO2021057987A1 (zh) 2019-09-27 2020-09-27 检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途

Country Status (2)

Country Link
CN (1) CN112578122B (zh)
WO (1) WO2021057987A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113584148A (zh) * 2021-06-30 2021-11-02 吉林大学 用于无精子症和严重少精子症检测的特异性标志物筛选方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062663A1 (en) * 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
CN110208544A (zh) * 2019-06-20 2019-09-06 南方医科大学深圳医院 一种粪便检测试纸及试剂盒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
AU2010276392A1 (en) * 2009-07-20 2012-03-08 Genentech, Inc. Gene expression markers for Crohn's disease
RU2012119756A (ru) * 2009-10-15 2013-11-20 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
CN103207274B (zh) * 2013-04-28 2015-02-25 成都中医药大学 一种胎儿7号染色体异常疾病的筛查试剂盒
CN105842459A (zh) * 2016-03-24 2016-08-10 泰州海路生物技术有限公司 快速定量检测粪便钙卫蛋白的免疫层析试剂盒

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062663A1 (en) * 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
CN110208544A (zh) * 2019-06-20 2019-09-06 南方医科大学深圳医院 一种粪便检测试纸及试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASAYUKI SHIMADA ET AL.: "Anti-Bacterial Factors Secreted from Cumulus Cells of Ovulated Cocs Enhance Sperm Capacitation during in vitro Fertilization", AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 69, no. 2, 28 February 2013 (2013-02-28), pages 168 - 179, XP055793968 *

Also Published As

Publication number Publication date
CN112578122B (zh) 2022-08-02
CN112578122A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
Kendrick et al. Theophylline improves steroid sensitivity in acute alcoholic hepatitis
Brubel et al. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders
WO2021057987A1 (zh) 检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途
AU2006209250A1 (en) Method for diagnosing tumours
EP3094973B1 (en) Biomarkers
WO2013191146A1 (ja) 悪性黒色腫（メラノーマ）の診断キット
WO2021057988A1 (zh) 检测粪钙卫蛋白含量的试剂在制备输卵管病变筛查试剂盒中的用途
WO2021057985A1 (zh) 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途
WO2021057986A1 (zh) 检测粪钙卫蛋白含量的试剂在制备卵巢病变筛查试剂盒中的用途
Hongyan et al. A study on clinical and pathologic features in lupus nephritis with mainly IgA deposits and a literature review
CN103926406A (zh) 一种指示肝炎感染的标志物及其用途
JP6192177B2 (ja) 炎症性腸疾患のバイオマーカーとしてのｓ１００ａ９の使用
Dalquen Fast Facts: The Essentials of Cytopathology
Musa Determining the Role of Urine Investigations in Urology Practice
Gondo Mastutik et al. The expression of E6 HPV, P53 and P16ink4a at well, moderately, and poorly differentiated cervical adenocarcinoma
Farag et al. Plasma beta2 microglobulin as a marker of progression in chronic Kidney disease patients
CN111690730B (zh) Il-8阳性初始t细胞作为诊断胸腺占位性疾病的靶点的应用
Cebeci et al. Podocyte injury in autosomal dominant polycystic kidney disease
Ekici et al. Benign mixed epithelial and stromal tumor of the kidney
Li et al. Endometrial carcinoma
CN105116152B (zh) 一种人源性尿液Endocan蛋白的ELISA检测试剂盒及检测方法
Mohammed Determination of Serum IL-8 Level in Women with Breast Cancer and Their Correlation With Disease Progression
Prabhu et al. Prevalence of crystalluria and its association with Escherichia coli urinary tract infections
Khudhur et al. Investigation of lipocalin2 and calprotectin in Ulcerative colitis patients
Başkıran et al. Investıgatıon of Kın of Irre-Lıke Proteın Levels In Patıents of Preeclampsıa: A Case-Control Study

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20870106

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20870106

Country of ref document: EP

Kind code of ref document: A1